Dietary Habits and Physical Activity are Associated With the Risk of Breast Cancer Among Young Iranian Women: A Case-control Study on 1010 Premenopausal Women.

Abstract:

BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or limited knowledge is available from the developing world. PATIENTS AND METHODS:This case-control study was performed from November 2014 to March 2016 on 1010 young women aged 20 to 50 years who were newly diagnosed with BC. Data was obtained via a validated questionnaire and the global physical activity questionnaire (GPAQ2). Also, patients' medical and histopathology reports were reviewed. RESULTS:The results of multiple logistic regression suggested that, except for the common risk factors for BC (older marital age, family history of BC, smoking, and being a passive smoker), eating red meat (adjusted odds ratio [aOR] >8 portions/week [p/w] vs. 0-2 p/w, 1.15; 95% confidence interval [CI], 1.04-1.28); eating fish (aOR >8 p/w vs. 0-2 p/w, 1.55; 95% CI, 1.12-2.76), fruit consumption (aOR 0-4 p/w vs. >8 p/w, 1.96; 95% CI, 1.07-3.82), pickle consumption (aOR >8 p/w vs. 7-8 p/w, 1.46; 95% CI, 1.31-1.70), and intensity of physical activity (aOR light vs. vigorous, 1.68; 95% CI, 1.47-1.98) were directly associated with a higher risk of BC in young women. CONCLUSION:Our study supported the hypothesis that unhealthy dietary habits and physical inactivity are risk factors for BC. We found that a healthy diet containing low fat and high fruits and vegetables with regular exercise are effective ways to reduce the risk of BC among young women.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Fararouei M,Iqbal A,Rezaian S,Gheibi Z,Dianatinasab A,Shakarami S,Dianatinasab M

doi

10.1016/j.clbc.2018.10.011

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

e127-e134

issue

1

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(18)30622-0

journal_volume

19

pub_type

杂志文章
  • Isolated sternal involvement in breast cancer: is it truly stage IV disease?

    abstract:PURPOSE:There is no consensus regarding treatment for patients with breast cancer and isolated sternal involvement. Though classified as AJCC stage IV, this group of patients may have prolonged distant disease free survival. PATIENTS AND METHODS:Retrospective case series of 8 patients with isolated sternal recurrence....

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2011.03.017

    authors: Chockalingam P,Astrow AB,Klein P,Huang Y,Reichman BS,Citron ML

    更新日期:2011-06-01 00:00:00

  • Breast Cancer and Ovulation Induction Treatments.

    abstract:BACKGROUND:This study was performed to determine whether the use of ovulation induction drugs in treatment of infertility have a significant effect on the risk of breast cancer. PATIENTS AND METHODS:This case control study (928 cases, 928 controls), was performed in the gynecology and oncology clinics of Shahid Behesh...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.03.003

    authors: Taheripanah R,Balash F,Anbiaee R,Mahmoodi M,Akbari Sene A

    更新日期:2018-10-01 00:00:00

  • Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.

    abstract:BACKGROUND:Elderly patients form a large proportion of patients with breast cancer but are underrepresented in clinical trials. We examined whether elderly patients experience more toxicity than younger patients within breast cancer clinical trials. MATERIALS AND METHODS:All breast cancer trials open from 1999 to 2012...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2014.09.002

    authors: Mariano C,Francl M,Pope J,Wong L,Lim HJ,Lohrisch C

    更新日期:2015-02-01 00:00:00

  • Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

    abstract:BACKGROUND:We investigated the effect of basal protein expression on trastuzamab response in patients with HER2-positive (HER2(+)) breast cancer who received trastuzamab (T) and in HER2(+) breast cancer cell lines. PATIENTS AND METHODS:Expression of cytokeratin (CK) 5/6, CK14, and epidermal growth factor receptor (EGF...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.001

    authors: Chung A,Choi M,Han BC,Bose S,Zhang X,Medina-Kauwe L,Sims J,Murali R,Taguiam M,Varda M,Schiff R,Giuliano A,Cui X

    更新日期:2015-12-01 00:00:00

  • A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

    abstract:BACKGROUND:Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotox...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clbc.2015.10.005

    authors: Gómez HL,Neciosup S,Tosello C,Mano M,Bines J,Ismael G,Santi PX,Pinczowski H,Nerón Y,Fanelli M,Fein L,Sampaio C,Lerzo G,Capó A,Zarba JJ,Blajman C,Varela MS,Martínez-Mesa J,Werutsky G,Barrios CH

    更新日期:2016-02-01 00:00:00

  • Taxanes and capecitabine in combination: rationale and clinical results.

    abstract::The clinical utility of capecitabine as a single agent in metastatic breast cancer has been demonstrated with significant responses seen in women already treated with anthracyclines and taxanes. A phase II study in older women with metastatic breast cancer demonstrated capecitabine to be an effective front-line therap...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2002.n.004

    authors: Maher JF,Villalona-Calero MA

    更新日期:2002-01-01 00:00:00

  • The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiotherapy.

    abstract:BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.05.007

    authors: Escott CE,Zaenger D,Switchencko JM,Lin JY,Abugideiri M,Arciero CA,Pfister NT,Xu KM,Meisel JL,Subhedar P,Torres M,Curran WJ,Patel PR

    更新日期:2020-12-01 00:00:00

  • Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.

    abstract:BACKGROUND:The prognostic/predictive value of aberrant MYC gene copies and protein expression is not clear in breast cancer. PATIENTS AND METHODS:Early breast cancer patients were treated with anthracycline-containing chemotherapy within 2 randomized adjuvant trials. MYC gene and centromere-8 status, as well as Myc pr...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clbc.2017.07.004

    authors: Batistatou A,Kotoula V,Bobos M,Kouvatseas G,Zagouri F,Tsolaki E,Gogas H,Koutras A,Pentheroudakis G,Timotheadou E,Pervana S,Goussia A,Petraki K,Sotiropoulou M,Koletsa T,Razis E,Kosmidis P,Aravantinos G,Papadimitriou C

    更新日期:2018-02-01 00:00:00

  • Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.

    abstract:INTRODUCTION:Emerging research suggests a substantially greater prevalence of the adverse triple-negative (TN) subtype (human epidermal growth factor receptor [HER]2(-), estrogen receptor [ER](-), and progesterone receptor [PR])(-)) among black patients with breast cancer. No reports however have been generated from a ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2011.04.004

    authors: Swede H,Gregorio DI,Tannenbaum SH,Brockmeyer JA,Ambrosone C,Wilson LL,Pensa MA,Gonsalves L,Stevens RG,Runowicz CD

    更新日期:2011-10-01 00:00:00

  • Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology.

    abstract:BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.08.004

    authors: Azim HA,Abdel-Malek R,Kassem L

    更新日期:2018-04-01 00:00:00

  • Impact of Detection Method and Age on Survival Outcomes in Triple-Negative Breast Cancer: A Population-Based Cohort Analysis.

    abstract:BACKGROUND:Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to exami...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.04.013

    authors: Rayson D,Payne JI,Michael JCR,Tsuruda KM,Abdolell M,Barnes PJ

    更新日期:2018-10-01 00:00:00

  • Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.

    abstract:BACKGROUND:To date, there have been no analyses to assess factors that influence post-mastectomy radiation therapy (PMRT) utilization in invasive lobular carcinoma (ILC) or to quantify the benefit of PMRT in ILC as compared with invasive ductal carcinoma (IDC). We compared histology-specific utilization of PMRT by tumo...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.02.001

    authors: Stecklein SR,Shen X,Mitchell MP

    更新日期:2016-08-01 00:00:00

  • Use of Adjuvant Breast Hypofractionation Radiation Treatment at a Cancer Center in Ontario From 2011 to 2018.

    abstract:BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.03.006

    authors: Lam E,Chan S,Karam I,Lee J,Wong G,Zhang L,Vesprini D,Wronski M,Chin L,Razvi Y,McKenzie E,Rakovitch E,Chow E

    更新日期:2020-10-01 00:00:00

  • Delayed resolution of jaundice in the arm of a patient with impaired lymphatic drainage: a case report.

    abstract::A 40-year-old woman, 6 years after mastectomy, lymph node dissection, and locoregional radiation, presented with hepatic metastases, pruritus, and jaundice. Physical examination revealed uniformly jaundiced skin and no arm lymphedema. Ultrasonography confirmed progressive hepatic metastases with no evidence of intrahe...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2007.n.055

    authors: Tsang RY,Mackey JR

    更新日期:2007-12-01 00:00:00

  • Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.

    abstract:BACKGROUND:Triple-negative breast carcinoma is defined by a primary tumor that is estrogen receptor negative, progesterone receptor negative, and HER2 negative. The current study was performed to determine the relationship of triple-negative tumor status to outcome after breast conservation treatment with radiation. P...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2009.n.018

    authors: Solin LJ,Hwang WT,Vapiwala N

    更新日期:2009-05-01 00:00:00

  • Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.

    abstract:BACKGROUND:The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-negative (HER(-)) metastatic breast cancer (MBC). PATIENTS AND METHODS:Patients (42) enrolled in trial A received intravenous (i.v.) VNR 25 mg/m2 on ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2011.11.001

    authors: Strada MR,Palumbo R,Bernardo A,Riccardi A,Teragni C,Poggi G,Frascaroli M,Amatu A,Montagna B,Sottotetti F,Tagliaferri B,Bernardo G

    更新日期:2012-02-01 00:00:00

  • Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.

    abstract:BACKGROUND:We examined tumor genotype characteristics of human epidermal growth factor receptor 2 (HER2)-positive relapsed (R-) and de novo (dn-) metastatic breast cancer (MBC) in trastuzumab-treated patients who were previously not exposed to this agent. MATERIALS AND METHODS:We analyzed genotypes obtained upon deep ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.10.014

    authors: Kotoula V,Tsakiri K,Koliou GA,Lazaridis G,Papadopoulou K,Giannoulatou E,Tikas I,Christodoulou C,Chatzopoulos K,Bobos M,Pentheroudakis G,Tsolaki E,Batistatou A,Kotsakis A,Koutras A,Linardou H,Razis E,Res E,Pectasides D

    更新日期:2019-04-01 00:00:00

  • Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3.

    abstract:BACKGROUND:Patients with breast cancer with pathologic N3 (pN3) lymph node status have been proven to have a poor prognosis. This study aimed to establish a nomogram to predict overall survival (OS) in patients with pN3 breast cancer. MATERIALS AND METHODS:The eligible patients from the Surveillance, Epidemiology, and...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.06.002

    authors: Wang J,Chen L,Nie Y,Wu W,Yao Y

    更新日期:2020-12-01 00:00:00

  • Equivalent Survival With Mastectomy or Breast-conserving Surgery Plus Radiation in Young Women Aged < 40 Years With Early-Stage Breast Cancer: A National Registry-based Stage-by-Stage Comparison.

    abstract:BACKGROUND:Studies have shown that young patients with early-stage breast cancer (BC) are increasingly undergoing mastectomy instead of breast-conserving therapy (BCT) consisting of lumpectomy and radiation. We examined the difference in outcomes in young women (aged < 40 years) who had undergone BCT versus mastectomy....

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.03.012

    authors: Ye JC,Yan W,Christos PJ,Nori D,Ravi A

    更新日期:2015-10-01 00:00:00

  • Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.

    abstract:BACKGROUND:In first-line treatment of metastatic breast cancer, the best use of the available therapeutic agents is unclear. This study evaluated the efficacy and safety of combined therapy with bevacizumab and gemcitabine. PATIENTS:Women who were to undergo first-line treatment for locoregionally recurrent or metasta...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2012.07.004

    authors: Borson R,Harker G,Reeves J,Beck T,Hager S,Horvath W,Jones M,Tillinghast G,Arrowsmith E,Harrer G,Kudrik FJ,Malamud SC,Bromund J,Zeigler H,Tai DF,Kornberg LJ,Obasaju C,Orlando M,Yardley DA

    更新日期:2012-10-01 00:00:00

  • Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

    abstract:BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.035

    authors: Kelly H,Kimmick G,Dees EC,Collichio F,Gatti L,Sawyer L,Ivanova A,Dressler L,Graham ML,Carey LA

    更新日期:2006-08-01 00:00:00

  • Digital mammography: a review of technical development and clinical applications.

    abstract::For detecting and diagnosing breast cancer at its earliest stage, mammography is the most sensitive technique currently available and is therefore the method of choice. Screen-film mammography has been used successfully as a screening test for breast cancer for > 2 decades. However, conventional mammography has substa...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2003.n.013

    authors: Shah AJ,Wang J,Yamada T,Fajardo LL

    更新日期:2003-04-01 00:00:00

  • Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

    abstract:PURPOSE:This multicenter phase II trial evaluated the efficacy and safety of weekly nanoparticle albumin-bound paclitaxel with carboplatin and weekly trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer (MBC). PATIENTS AND METHODS:We treated 32 patients who had measurable MBC t...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CBC.2010.n.036

    authors: Conlin AK,Seidman AD,Bach A,Lake D,Dickler M,D'Andrea G,Traina T,Danso M,Brufsky AM,Saleh M,Clawson A,Hudis CA

    更新日期:2010-08-01 00:00:00

  • Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    abstract:BACKGROUND:The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC). PATIENTS...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.09.014

    authors: Chan A,Moy B,Mansi J,Ejlertsen B,Holmes FA,Chia S,Iwata H,Gnant M,Loibl S,Barrios CH,Somali I,Smichkoska S,Martinez N,Alonso MG,Link JS,Mayer IA,Cold S,Murillo SM,Senecal F,Inoue K,Ruiz-Borrego M,Hui R,Dendulu

    更新日期:2020-10-06 00:00:00

  • Fertility and menopausal outcomes in young breast cancer survivors.

    abstract:BACKGROUND:Following treatment for breast cancer, many young women are interested in having a child. There are few data available regarding actual fertility and menopausal outcomes in young breast cancer survivors. We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2008.n.004

    authors: Partridge AH,Gelber S,Peppercorn J,Ginsburg E,Sampson E,Rosenberg R,Przypyszny M,Winer EP

    更新日期:2008-02-01 00:00:00

  • Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy.

    abstract:BACKGROUND:Ovarian suppression from chemotherapy results in bone loss in premenopausal women with breast cancer (BC). Less is known about bone microarchitecture changes. We used high-resolution peripheral quantitative computed tomography (HR-pQCT) to measure volumetric bone density and trabecular and cortical microarch...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.12.001

    authors: Hopson MB,Onishi M,Awad D,Buono D,Maurer M,Crew KD,Shane E,Hershman DL,Kalinsky K

    更新日期:2020-06-01 00:00:00

  • Rheumatic disorders and functional disability with aromatase inhibitor therapy.

    abstract:BACKGROUND:Aromatase inhibitor therapy is often effective for breast cancer, yet it can be accompanied by musculoskeletal pain and stiffness. This prevalence assessment aimed to characterize a rheumatologist's view of frequency and clinical features, including associated disability, within a breast cancer clinic panel ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2010.n.019

    authors: Moxley G

    更新日期:2010-04-01 00:00:00

  • Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.

    abstract:BACKGROUND:In this analysis we compared quality-adjusted survival outcomes between nab-paclitaxel (nab-P) and standard paclitaxel (Pac) using data from the nab-P phase III registration trial in metastatic breast cancer. PATIENTS AND METHODS:Quality-adjusted overall survival was estimated using the quality-adjusted tim...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.03.014

    authors: Cortes J,Pérez-García J,Whiting S,Wan Y,Solem C,Tai MH,Margunato-Debay S,Ko A,Fandi A,Botteman M

    更新日期:2018-10-01 00:00:00

  • Transcription Factor EB Expression in Early Breast Cancer Relates to Lysosomal/Autophagosomal Markers and Prognosis.

    abstract:BACKGROUND:Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior. METHODS:The expression of TFEB and the lysosomal cancer cell con...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.11.006

    authors: Giatromanolaki A,Sivridis E,Kalamida D,Koukourakis MI

    更新日期:2017-06-01 00:00:00

  • Timing of Postmastectomy Reconstruction Does Not Impair Breast Cancer-Specific Survival: A Population-Based Study.

    abstract:BACKGROUND:Debate remains over the optimal timing of breast reconstruction after mastectomy. Immediate reconstruction has demonstrated superior psychosocial and aesthetic outcomes, but might delay adjuvant therapy. Conversely, delayed reconstruction allows for timely initiation of adjuvant therapy, but with potentially...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.06.003

    authors: Bezuhly M,Wang Y,Williams JG,Sigurdson LJ

    更新日期:2015-12-01 00:00:00